Ryan Lynch (@Rcl14L) header
Ryan Lynch (@Rcl14L) profile picture

Ryan Lynch

@Rcl14L
 Seattle, WA
Joined September 2013
  • Tweets2.1K
  • Following238
  • Followers235
Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma. Co-authored by @AshAlizadeh, @RoschewskiMD, @DrJasonWestin, @max_diehn, @Rcl14L Read the full article. brnw.ch/21wV02q #lymsm
Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma

Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma

PURPOSELarge B-cell lymphomas (LBCLs) are curable, but patients with residual disease after therapy invariably experience progression. Ultrasensitive methods to detect circulating tumor DNA (ctDNA)...

ascopubs.org
14
1
40
6,543
We’re hiring! Fred Hutch/UW is recruiting a faculty member focused on T-cell lymphomas. Join a top-tier, collaborative lymphoma team with strong clinical + research support. Please share or reach out for details! apply.interfolio.com/168236 #HemOnc #Lymphoma #TCellLymphoma #AcademicMedicine @fredhutch @uwmnewsroom
4
16
5,272
Fantastic commentary from @BroeckelmannPJ on considerations on the use of PD1i in the frontline treatment of Hodgkin lymphoma.
Kate Cwynarski (@CwynKate) profile pictureKate Cwynarski@CwynKate17 May 2024
British Journal of Haematology | Wiley Online Library onlinelibrary.wiley.com/doi/… onlinelibrary.wiley.com/shar… @BroeckelmannPJ 👏
Considerations for anti‐PD1‐based first‐line treatment of Hodgkin lymphoma

Considerations for anti‐PD1‐based first‐line treatment of Hodgkin lymphoma

Anti-PD1-based first-line treatment holds great promise in classical Hodgkin lymphoma. The management of immune-related adverse events in the context of time-limited combined checkpoint blockade and...

onlinelibrary.wiley.com
6
16
3,155
Ryan Lynch retweeted
ASH (@ASH_hematology) profile picture
ASH
@ASH_hematology5 Feb 2024
Combination treatments with two or more blood pressure drugs can significantly reduce blood pressure in patients taking ibrutinib, according to a new study in @BloodAdvances. Read more: ow.ly/Xf6K50QxUuf @mshadman @LauraSamplesMD @fredhutch
Image from ASH (@ASH_hematology)
8
2
20
12,469
Day 4 @icmlugano #ICML2023 Oral presentation A “FUNCTIONAL CURE” MAY BE ACHIEVABLE IN A SUBSET OF PATIENTS WITH FOLLICULAR LYMPHOMA TREATED WITH CHEMOIMMUNOTHERAPY: 15-YEAR FOLLOW-UP OF PHASE III SWOG-S0016 onlinelibrary.wiley.com/doi/… @SWOG @DrJFriedberg @fredhutch @SoniSmithMD
A “FUNCTIONAL CURE” MAY BE ACHIEVABLE IN A SUBSET OF PATIENTS WITH FOLLICULAR LYMPHOMA TREATED WITH...

A “FUNCTIONAL CURE” MAY BE ACHIEVABLE IN A SUBSET OF PATIENTS WITH FOLLICULAR LYMPHOMA TREATED WITH...

Click on the article title to read more.

onlinelibrary.wiley.com
1
8
28
5,529
We are pleased to present the results of our phase I study substituting polatuzumab vedotin for vincristine in the DA-EPOCH-R regimen. Officially called Pola-DA-EPCH-R, it has gained the nickname “PERCH” @UjjaniC @mshadman @fredhutch @UWMedicine ashpublications.org/bloodadv…
Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin...

Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin...

Key Points. Pola-DA-EPCH-R has an acceptable safety profile that is similar to that of previously published results of the standard DA-EPOCH-R regimen.Subs

ashpublications.org
2
13
43
10,122
more replies
We want to thank our patients, clinical teams, and research staff. I also want to acknowledge @lymphoma for their support through a career development award.
1
304
@poh_christina
318
Load more